In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).